ClinicalTrials.gg
CompletedNCT00247663Updated Apr 19, 2012

Extension Study of 1.0mg Dose Letrozole Therapy in Postmenopausal Patients With Breast Cancer

A Phase 2 interventional study of Letrozole in Postmenopausal Women With Advanced Breast Cancer, sponsored by Novartis Pharmaceuticals. Completed at 10 sites in Japan. Open to female participants aged 20 Years to 74 Years. Per ClinicalTrials.gov, last updated 2012-04-19.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
17
Allocation
Not applicable
Ages
20 Years to 74 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 162 studies testing letrozole in Breast Neoplasms — 22 open to participants now, 39 under way, 11 of them phase 3. Letrozole · Breast Neoplasms.

Enrollment
138th of 159
17 · median 95
Started
1999
the only one that year
Phase 2
72 of 162
13 open now
Registered
25th of 162
by date
Lead sponsor
21 of 162
Novartis Pharmaceuticals

Among the 162 studies testing letrozole in Breast Neoplasms, this one is the 138th largest by enrollment of the 159 interventional ones that give a count, is the only one that started in 1999, is one of 72 in phase 2, and was the 25th registered.

Breast Neoplasms

14,832 studies on the registry are indexed under Breast Neoplasms; 3,322 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

22 of the 162 studies testing letrozole in Breast Neoplasms are open now, in 12 countries. Recruiting first, the newest first:

17 more — sign in →

By country, each count listing its studies:

All 22 open studies →

About letrozole

Letrozole: first FDA approval 1997 (FEMARA). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 2,400 Breast Neoplasms studies recruiting now, 1,572 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 214 take healthy volunteers.

This study: 20 Years to 74 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 162 studies testing letrozole in Breast Neoplasms, or all of them as a file.
02

Study summary

  • To investigate the safety of letrozole monotherapy at a dose 1.0 mg/day or fadrozole monotherapy at a dose 2.0mg in Japanese postmenopausal patients with advanced breast cancer which participated in double blind study.
03

Conditions studied

  • Postmenopausal Women With Advanced Breast Cancer

Browse trials for

Keywords

  • Aromatase inhibitor
  • letrozole
  • breast cancer
04

Who can participate

Ages eligible
20 Years to 74 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients which participated in double blind study

Exclusion criteria

Exclusion Criteria:

  • Patients with intolerable toxicity.
  • Patients which confirmed progressive disease during double blind study.
  • Patients which have received concurrent anti-cancer therapy during double blind study.
05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
17 participants (actual)

Study arms

  • Experimental
    Letrozole

    Drug: Letrozole

Interventions

06

What researchers measure

Primary outcomes

  1. Safety during treatment

Secondary outcomes

  1. No secondary outcomes/objectives planned

07

Study locations

10 sites
  • Novartis Investigative Site
    Kashiwa, Chiba 277-8577, Japan
  • Novartis Investigative Site
    Amagasaki, Hyogo 660-8511, Japan
  • Novartis Investigative Site
    Hamamatsu, Shizuoka 430-8558, Japan
  • Novartis Investigative Site
    Chuo-Ku, Tokyo 104-0045, Japan
  • Novartis Investigative Site
    Cyuo-ku, Tokyo 104-8560, Japan
  • Novartis Investigative Site
    Shinjuku-ku, Tokyo 160-8582, Japan
  • Novartis Investigative Site
    Fukuoka, 811-4395, Japan
  • Novartis Investigative Site
    Kumamoto, 862-0909, Japan
  • Novartis Investigative Site
    Nigata, 951-8566, Japan
  • Novartis Investigative Site
    Saitama, 338-8553, Japan
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 1999 and a primary completion of Dec 2005. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 1, 2005
First posted
Nov 2, 2005
Start
Dec 1999
Primary completionActual
Dec 2005
Last update
Apr 19, 2012
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 19, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00247663
Responsible party
Sponsor
First posted
Nov 2, 2005
Start date
Dec 1999
Primary completion
Dec 2005
Last update
Apr 19, 2012

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Letrozole

Start the discussion